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Abstract
Oligodendrocytes, the myelin-forming glial cells of the central nervous system (CNS), are
fundamental players in rapid impulse conduction and normal axonal functions. JunB and c-
Jun are DNA-binding components of the AP-1 transcription factor, which is known to regu-
late different processes such as proliferation, differentiation, stress responses and death in
several cell types, including cultured oligodendrocyte/lineage cells. By selectively inactivat-
ing Jun B and c-Jun in myelinating oligodendrocytes in vivo, we generated mutant mice that
developed normally, and within more than 12 months showed normal ageing and survival
rates. In the adult CNS, absence of JunB and c-Jun from mature oligodendrocytes caused
low-grade glial activation without overt signs of demyelination or secondary leukocyte infil-
tration into the brain. Even after exposure to toxic or autoimmune oligodendrocyte insults,
signs of altered oligodendrocyte viability were mild and detectable only upon cuprizone
treatment. We conclude that JunB and c-Jun expression in post-mitotic oligodendrocytes is
mostly dispensable for the maintainance of white matter tracts throughout adult life, even
under demyelinating conditions.
Introduction
The transcription factors c-Jun and JunB are key components of the activator protein-1 (AP-1)
transcription factor complex and form, together with JunD, the Jun protein family (reviewed in
[1,2]). N-terminal phosphorylation of c-Jun by c-Jun N-terminal kinases (JNK) can alter AP-1
binding activity in the absence of de novo protein synthesis, but c-Jun has also phosphoryla-
tion-independent functions [3,4,5]. Proteins of the Jun family are critical regulators of multiple
cellular processes including differentiation, proliferation, and apoptosis, often with opposing
outcomes depending on the cellular context (reviewed in [6]). Germ-line deletion of c-Jun
leads to embryonic lethality [7,8]. However, JunB flox/flox [9] and c-Junflox/flox [10] mice have
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been used to selectively inactivate Jun proteins in various cell types and tissues, including skin
(K5-cre-ERT; [11]), liver (albumin-cre/Mx-cre; [10]), peripheral nerve glia (P0-cre; [12,13]) and
nervous tissue (early neuroepithelial nestin-cre; [14]; neuronal syn-cre; [5]). This transgenic
cre-lox approach thus allowed to describe some of the fundamental roles of Jun proteins in sev-
eral pathological conditions, as in psoriatic skin lesions in which epidermal keratinocytes show
decreased expression of JunB, and inducible epidermal deletion of JunB and c-Jun causes a ful-
minant psoriasis-like skin disease and arthritis in mice [11].
c-Jun expression in glial Schwann cells plays a critical role in repair responses after nerve in-
jury in the peripheral nervous system (PNS), which is known to have a high regenerative capac-
ity compared to the CNS [12,13]. Deletion of c-Jun using a Cre-recombinase driven by the
nestin promotor decreases efficient axonal regeneration after transsection of the facial nerve
[14], and selective inactivation of c-Jun in Schwann cells impairs axon re-growth and nerve tar-
get re-innervation after injury, as well as myelin clearance by macrophages. Despite these inju-
ry-related functions of c-Jun, absence of the gene did not affect normal Schwann cell and nerve
functions in adult uninjured mice [13].
In contrast to the PNS, the final effect of Jun proteins on oligodendroglial fate in the CNS re-
mains controversial. While some investigators show that induction of c-Jun by nerve growth
factor or tumor necrosis factor (TNF) in oligodendrocytes correlates with apoptosis in vitro
[15,16], others report activation of JNK without apoptosis by TNF in astrocyte and oligoden-
drocyte cultures [17]. In active multiple sclerosis (MS) lesions, up-regulation of nuclear stain-
ing for c-Jun/JNK proteins on a large proportion of oligodendrocytes located at the edge of
active lesions has been described [18]. The concomitant absence of oligodendroglial cell death
would speak against a direct role of c-Jun in the apoptotic process of these glial cells.
To further elucidate the function of AP-1 proteins in oligodendrocyte biology in the adult
CNS in vivo, we used mutants with oligodendrocyte-specific deletion of JunB and c-Jun (at late
myelinating stages in these cells). We examined the role of these factors in the uninjured CNS,
and after inducing oligodendrocyte damage by mitochondrial impairment [19] following
cuprizone application and induction of myelin-directed autoimmunity. Our study indicates,
that oligodendroglial JunB and c-Jun have at the most a minor protective effect on oligoden-
drocyte survival and myelination, even upon demyelinating insults. Nevertheless, our data do
underscore the tissue- and context-dependent differences in Jun protein function in vivo, and
the fact that they often can only incompletely be predicted by in vitro studies on primary/
lineage cells.
Materials and Methods
Mice and genotyping
All animal experiments were specifically approved by the Institutional Animal Care and Use
Committee and Swiss Cantonal Veterinary Office (License 86/2012, Zurich, Switzerland). Mice
carrying a floxed JunB allele (junBf/f; [9]) and/or floxed c-Jun allele (c-junf/f; [10]) were crossed
to transgenic mice animals expressing the Cre recombinase under the control of the oligoden-
drocyte-specific MOG promoter (MOGi-cre; [20]) to obtain JunBf/f c-Junf/f MOGi-cremice
(JunBΔol/c-JunΔol double mutants). Sibling animals lacking the Cre transgene, with functional,
unrecombined homozygous JunB and c-Jun (JunBf/f/c-Junf/f), served as controls. CO2 inhala-
tion was used as method of euthanasia.
The primer sequences for genotyping were:MOGi-cre (WT 350 bp): GAC AAT TCA GAG
TGA TAG GAC CAG GGT ATC CC and GCT GCC TAT TAT TGG TAA GAG TGG;MOGi-
cre (knock-in, 700 bp): TCC AAT TTA CTG ACC GTA CAC and CAT CAG CTA CAC CAG
AGA CGG AAA TC; JunB (WT 299 bp, floxed 384 bp): ATC CTG CTG GGA GCG GGG
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AAC TGA GGG AGG and AGA GTC GTC GTG ATA GAA AGG C; JunB (WT 1490 bp,
floxed 1575 bp, Δ 300 bp): GGG AAC TGA GGG AAG CCA CGC CGA GAA AGC and AAA
CAT ACA AAA TAC GCT GG; c-Jun (WT 300 bp, floxed 350 bp, Δ 600 bp): CAG GGC GTT
GTG TCA CTG AGC T and CTC ATA CCA GTT CGC ACA GGC GGC and CCG CTA GCA
CTC ACG TTG GTA GGC.
Western Blot analysis
CNS tissues were lysed in cell lysis buffer (Cell Signaling), supplemented with cOmplete Prote-
ase Inhibitor Cocktail and PhosSTOP Phospatase inhibitors (both Roche), for 30 min, sonicat-
ed and centrifuged at 14`000 x g at 4°C for 30 min. After BCA assay (Thermo Scientific),
proteins were blotted and detected with the following antibodies: mouse anti-Vinculin (loading
control, 1: 20`000, clone hVIN-1, Sigma), rabbit polyclonal anti-junB (1:250, Santa Cruz, sc-
46) and mouse anti-c-jun (1:1`000, clone 3/Jun, BD Transduction Laboratories).
Scoring of motor performance
In RotaRod experiments, the average time to fall was measured during a 5–50 rpm acceleration
over 3 min (n = 3). In the walking grid test, we counted the number of footfalls over a 50-cm-
long runway with irregularly arranged bars (0.5–2.5 cm) on a 10-cm distance. Mice were as-
signed EAE scores daily as follows: 0, no detectable signs of EAE; 0.5, distal tail limp; 1, com-
plete tail limp; 2, unilateral partial hindlimb paralysis; 2.5, bilateral partial limb paralysis; 3,
complete bilateral hindlimb paralysis; 3.5, complete hindlimb paralysis and unilateral forelimb
paralysis; 4, total paralysis of forelimbs and hindlimbs (mice with a score above 4 to be eutha-
nized); 5, death.
Immunohistochemistry
CNS was perfused, fixed (4% FA in PBS) and after paraffin-embedding cut at 5 μm. Hematoxy-
lin and eosin and LFB-PAS staining were performed according to standard protocols. CNPase
(mouse, clone 11-5B, Chemicon/Millipore), polyclonal Iba-1 (rabbit, Wako) and polyclonal
GFAP (rabbit, DAKO) staining was performed by a Ventana Benchmark XT-automated stain-
ing according to the manufacturer's guidelines (iVIEW DAB Detection Kit, Ventana).
In order to evaluate demyelination, LFB-PAS stained brain sections of cuprizone treated
mice were scored in a blinded fashion from zero to three as described before [21]. Zero was
equivalent to the myelin status of a mouse not treated with cuprizone, whereas a score of three
was total demyelination of the corpus callosum. A score of 1 is equivalent to demyelination of
one third of the fibers, while a score of two is equivalent to demyelination of two thirds of the
fibers of the myelin tract. Iba-1+ microglial cells were counted manually in a blinded fashion.
Only cells that contained a nucleus, as indicated by hematoxylin counterstain, were counted.
Four sections per animal were analyzed and values averaged per mouse. EAE spinal cord sec-
tions were semi-quantitatively analyzed, assessing inflammation (H/E, lymphocytes: 0: none, 1:
mild, 2: moderate, 3: strong) and demyelination (LFB-PAS and CNPase: 0: none, 1: mild, 2:
moderate, 3: strong).
CNS flow cytometry
Mice were perfused using ice-cold PBS and brainstem with cerebellum and spinal cords were
collected. Tissues were cut into small pieces using scissors, followed by 30 min of digestion
with 0.8 mg/mL collagenase D (Roche) and 0.5 mg/mL DNAse (Sigma). Remaining pieces of
tissue were homogenized and filtered through a 100 μm-cell strainer. After washing, the cell
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suspension was loaded onto a continuous 30% Percoll (GE) gradient and centrifuged for
30 min at 15 000 × g. The myelin layer was removed carefully, and the remaining cell suspen-
sion spun down. Flow cytometric analysis was performed following standard methods. We
purchased 30-F11 (CD45) and M1/70 (CD11b) antibodies from BD Biosciences. In all stain-
ings, dead cells were excluded using an Aqua Live/Dead fixable staining reagent (Invitrogen),
and absolute cell numbers were determinded using AccuCheck Counting Beads (Life
Technologies).
Cuprizone Treatment
Eight to ten week old male mice were fed 0.2% to 0.4% wt/wt cuprizone (bis(cyclohexylidene-
hydrazide), C9012-25G, Sigma) to induce demyelination [22].
EAE induction
For EAE experiments 6 to 10 weeks old female mice were immunized subcutaneously with
200 μg (each flank 100 μg) of MOG35–55 peptide (MEVGWYRSPFSRVVHLYRNGK) emulsi-
fied in Complete Freund’s Adjuvant (CFA, H37 Ra, Difco laboratories), and injected i.p. the
same day and at day 2 with 200 ng pertussis toxin (Sigma).
Statistical analysis
Results are given as mean ± s.e.m. unless indicated otherwise. Statistical significance was deter-
mined with GraphPad Prism (GraphPad Software).
Results and Discussion
Generation of JunBΔol/c-JunΔol mice mice lacking Jun proteins in mature
oligodendrocytes
We aimed at studying the functions of JunB and c-Jun in mature oligodendrocytes in an in vivo
mouse model. Therefore, we generated animals with an oligodendrocyte specific deletion of the
JunB and c-Jun gene by crossing mice carrying LoxP-site-containing (floxed) JunB (JunBf/f)
and c-Jun (c-Junf/f) alleles with animals expressing the Cre recombinase under the control of
the myelin oligodendrocyte glycoprotein (MOG) promoter (Fig. 1A). As MOG is the last of
myelin proteins to be produced along oligodendrocyte maturation [23,24], genetic recombina-
tion in thisMOGi-cre strain is specific for terminally differentiated oligodendrocytes [25]. Pre-
vious studies have demonstrated the CNS specifity and efficiency of theMOGi-cre transgenic
line [20]. Because Cre/LoxP-mediated recombination can vary between different loxP-flanked
target genes, we analyzed genomic DNA of various organs of adultMOGi-cre+/- JunBf/f/c-Junf/f
(JunBΔol/c-JunΔol) mice by PCR. A 300- or 600-bp product corresponding to the deleted/re-
combined JunB or c-Jun gene was observed solely in DNA taken from CNS tissues, thus con-
firming CNS-specific recombination in this mouse strain (Fig. 1B). Significant JunBf or c-Junf
inactivation was not confined to a specific CNS region, as it was observed in brain (Br), cerebel-
lum (Cb) and spinal cord (Sc) (Fig. 1B). Furthermore, we tested the protein levels of JunB and
c-Jun in CNS lysates from spinal cord of three to four months-old JunBΔol/c-JunΔol mice. We
confirmed that the levels of JunB and c-Jun protein expressed in JunBΔol/c-JunΔol CNS spinal
cord tissues were reduced compared to Cre-negative floxed control mice (Fig. 1C).
Normal brain morphology and motor behaviour in JunBΔol/c-JunΔol mice
MOGi-cre+/- JunBf/f/c-Junf/f mice were born with Mendelian frequency (49% mutant pups com-
pared with 50% expected, n = 151) and were viable and fertile. Males and females presented
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with normal general health, and body weight as compared to control mice at three months of
age (male controls 31±0 vs mutants 32±1 g, p = 0.6082 and female controls 26±1 vs mutants
26±2 g; p = 0.9399) and up to more than 12 months postnatally (male controls 46±1 vs mutants
44±1 g, p = 0.2279 and female controls 50±1 vs mutants 52±2 g; p = 0.4738, unpaired, two-
tailed t-test; Fig. 2A). JunBΔol/c-JunΔol mice showed similar CNS cyto- and myelo-architecture
compared to controls (Fig. 2B and C) by H&E, LFB-PAS and myelin-associated CNPase stain-
ing at up to six to twelve months of age. We did not observe any apparent demyelination, even
though there was a mild increase in the number of activated microglia (Iba-1 staining: controls
34.3±4 vs mutants 45.4±5 Iba+ cells/visual field, p = 0.1601, unpaired t-test, n = 3–5 mice; for
quantifications see Fig. 2B) and mild reactive astrogliosis (GFAP) compared to Cre-negative
floxed control mice. Notably, absence of JunB and c-Jun from mature oligodendrocytes did not
cause infiltration of leukocytes into the brain (Fig. 2C, HE staining, and data not shown).
Moreover, deletion of JunB and c-Jun in oligodendrocytes did not lead to obvious neurological
deficits indicative of disturbed CNS myelin maintenance up to the age of more than one year
(Fig. 2D and E; maximal observation time was 19 months of age). In order to detect more suble
motor impairments, we challenged JunBΔol/c-JunΔol mice using a grid test (Fig. 2D). They
showed similar missteps per trial compared to controls (on average over 3 trials: male controls
2±0 versus mutants 2±0; p = 0.0988 and female controls 2±0 versus mutants 2±0, p = 0.9306
for genotype, matched two-way ANOVA). When we subjected the animals to the rotarod test-
ing, (Fig. 2E) motor performance was comparable in male and female JunBΔol/c-JunΔol mice
compared to Cre-negative floxed controls. However, there were signs of slight motor learning
Fig 1. Deletion of JunB and c-Jun in oligodendrocytes. (a) Schematic diagram of MOGiCre x JunBf/f and c-Junf/f (JunBΔol/Jun-cΔol) mice. (b) Genotyping
PCR using genomic DNA derived from various peripheral organs and CNS regions from a JunBflox/flox (top) and c-Junflox/flox (bottom) MOGiCre/+ mutant
(JunBΔol/c-JunΔol) and from a homozygous JunBflox/flox/c-Junflox/flox MOGiCre-negative control (JunBf/f/c-Junf/f). Li, liver; Ki, kidney, Spl, spleen; Hr, heart;
Thy, thymus, Lu, lung; Ln, lymph node; Br, brain; Cb, cerebellum; Sc, spinal cord. (c) Western Blot analysis for JunB, c-Jun and vinculin (loading control) in
protein lysates obtained from CNS spinal cord tissue of junBf/fc-Junf/f controls and JunBΔol/c-JunΔol double mutants (n = 2 individual animals per group).
doi:10.1371/journal.pone.0120454.g001
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deficits, in that male double mutants did improve their performance less during three consecu-
tive trials (male controls improved 1.4-fold, mutants 0.9-fold, p = 0.0109; female controls im-
proved 2.4-fold, mutants 1.8-fold, p = 0.3719, unpaired, two-tailed t-test; Fig. 2E). Thus,
Fig 2. Normal brain morphology andmotor skills. (a) Weight of littermate controls (JunBf/fc-Junf/f) (black bars) and JunBΔol/c-JunΔol double mutants (white
bars) at 3 and12 months of age. 22 controls and 30 mutants were analyzed in total. (b, c) Histological analysis (hematoxylin and eosin, HE and luxol fast
blue—periodic acid schiff staining, LFB-PAS) of control and mutant brain sections at 6–12 months of age (n4 per group; representative pictures are from
the corpus callosum brain region of 6 month old mice). Immunostaining for oligodendroglial CNPase, microglial Iba-1, and astrocytic GFAP. Scale bar,
50 μm. For quantifications of the number of Iba-1+ cells per visual field see (b) (n = 3–5 mice per group, unpaired t-test, n.s., not significant). (d, e) The grid
test (d) assessing limb strenght and subtle motor coordination deficits like slipping at12 months of age (n = 15 controls, and n = 13 double mutants). Motor
performance in the rotarod test (e) (3 consecutive trials; after 3 exercise trials the day before). Matched 2way ANOVA, Bonferroni post-test, n.s., not
significant; *P< 0.05.
doi:10.1371/journal.pone.0120454.g002
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staining for astrocytes and microglia gave an indication of low-grade inflammation in elderly
JunBΔol/c-JunΔol mutant mice, which is a very sensitive response to degenerative processes in
white matter tracts. However, we did not observe more prominent signs of oligodendrocyte
loss or demyelination by light microscopy criteria, nor clinically relevant motor deficits. Taken
together, the post-myelination CNS phenotype of adult JunBΔol/c-JunΔol double mutants mice
was mild, and oligodendrocytes seemed to be sufficiently able to maintain myelin.
Fig 3. Comparable cuprizone-induced demyelination after oligodendroglial deletion of JunB and c-Jun. (a) Representative images of JunBf/f/c-Junf/f
controls and JunBΔol/c-JunΔol double mutants that received cuprizone for 6 weeks. (b) The number of microglia and extent of demyelination was evaluated in
matched sections (n = 3–5 mice per group, n = 4 sections per mouse averaged, unpaired t-test). HE, LFB-PAS staining, as well as CNPase, Iba-1 and GFAP
immunoreactivity in the corpus callosum. Scale bar, 50 μm.
doi:10.1371/journal.pone.0120454.g003
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Fig 4. Similar clinical and histopathological EAE phenotype after oligodendroglial knock-out of JunB and c-Jun. (a) Day of onset and maximal
clinical EAE score in MOG35–55-immunized control (JunB
f/fc-Junf/f) and JunBΔol/c-JunΔol double mutants (n = 12–19, unpaired t-test). (b) Number of CD45high
leukocytes isolated from cerebellum/spinal cords of controls and mutant mice. Data were pooled from 2 independent experiments (n = 10 MOG peptide-
immunized mice per group and n = 4 naïve mutants, unpaired t-test). (c) Semiquantitative histology scores of inflammation and demyelination in spinal cords
of MOG peptide-immunized mutant mice (mean clinical EAE score 2.3) and controls (mean EAE score 2.0; n = 4 per group). (d) Representative images of
HE, LFB-PAS staining, as well as CNPase, Iba-1 and GFAP immunoreactivity in the spinal cords.
doi:10.1371/journal.pone.0120454.g004
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Comparable cuprizone-induced demyelination in JunBΔol/c-JunΔol and
control mice
To investigate JunB and c-Jun function in mature oligodendrocytes in response to a toxic de-
myelinating insult, we fed eight to ten week old JunBΔol/c-JunΔol mice with cuprizone [26]
(Fig. 3A and B). Cuprizone feeding damages oligodendrocytes progressively and dose-depen-
dently. It leads to consistent oligodendrocyte cell loss starting three weeks post-administration
(p.a.), accompanied by the first signs of demyelination [27]. We compared the effects of cupri-
zone feeding in JunBΔol/c-JunΔol double mutant and JunBf/f/c-Junf/f control mice at week six p.
a., when the corpus callosum generally is maximal demyelinated. At that time point, most of
our control mice showed robust and moderate to strong demyelination which affected one to
two thirds of the corpus callosum (LFB-PAS and CNPase staining), activated microglia (Iba-1)
and reactive GFAP-positive astrocytes. We did not detect significant leukocyte accumulation
(HE staining). Demyelination was similar in JunBΔol/c-JunΔol double mutant and control mice
(LFB-PAS/demyelination score: controls 1.3±0.3 vs mutants 1.2±0.2, p = 0.8176 for 0.2% cupri-
zone, and controls 1.7±0.4 vs mutants 1.6±0.7, p = 0.9126 for 0.4% cuprizone, unpaired t-test,
n = 3–5 mice; for quantifications see Fig. 3B). Notably, in two to three experiments in which
changes in control mice were more discrete (reactive astrocytes at week 4 p.a., no later demye-
lination or only moderate demyelination), we detected a minor increase in reactive gliosis and/
or demyelination in JunBΔol/c-JunΔol double mutants (GFAP-upregulation starting at week 2 p.
a., more pronounced microgliosis at later time points or more demyelination).
In addition, we challenged oligodendrocytes in JunBΔol/c-JunΔol CNS by triggering a T cell-
mediated immune attack against CNS myelin (MOG35–55 peptide-induced Experimental Auto-
immune Encephalomyelitis, EAE) (Fig. 4). In this mouse model for MS, demyelination and cell
death is observed to a variable degree predominantly in spinal cord and brain stem [28]. In dis-
eased mice, the day of onset of neurological deficits (n = 12–19, p = 0.2478, unpaired t-test)
and maximal clinical score (p = 0.9928) were similar in JunBΔol/c-JunΔol double mutant and
control mice (Fig. 4A). We assessed leukocyte infiltration (by flow cytometry staining for
CD45, Fig. 4B, and HE histochemistry, Fig. 4 C and D) and demyelination in EAE brains and
spinal cords of mice with similar acute disease severities (by LFB-PAS and CNPase staining,
n = 4 JunBΔol/c-JunΔol double mutants with an average clinical score of 2.3 and n = 4 controls
with an average score of 2.0;). As expected, leukocyte infiltration was prominent in the spinal
cords, but spinal demyelination comparably strong between double mutants and controls
(Fig. 4C and D).
Even though both, toxic cuprizone treatment and EAE, have limitations as models of
human chronic, slowly progressive demyelinating diseases, like MS (reviewed in [29]), the
cuprizone model can still provide insights into the determinants of oligodendrocyte death in
vivo, and EAE has proven very useful to study inflammatory aspects of MS. In this regard, this
study also speaks against the hypothesis, that loss of c-Jun and JunB in the adult CNS would
mirror what is observed in the skin, in that AP-1 dysfunction is not a strong universal trigger
of inflammation. That the survival of mature oligodendrocytes after demyelinating toxic
(cuprizone) or autoimmune insults (EAE) apparently is only slightly or not dependent on JunB
and c-Jun activity in vivo was unexpected based on previous studies of cultured oligodendro-
cyte/lineage cells. In fact, oligodendrocyte/lineage cell proliferation and process extension in
vitro seems to be impaired when overexpressing a dominant-negative c-Jun mutant [30]. In ad-
dition, JNK and AP-1 DNA-binding activity in cultured oligodendrocytes have been correlated
with apoptosis induced by different stimuli [30,31,32,33,34]. However, when glial cells are
maintained in tissue culture, their phenotype often changes considerably and they might not
fully reflect all properties of myelinated, mature oligodendrocytes in vivo [30,35]. Our work
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shows in an in vivomodel, that if JunB and c-Jun have any function in oligodendrocyte homeo-
stasis, it must be a redundant one.
We conclude that once myelination has occurred, reduced JunB and c-Jun functions do not
significantly perturb oligodendrocyte survival, or myelin maintenance in vivo.
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